To develop new drug targets for anti-angiogenic therapy, in this study, we proposed an integrated analytical approach for screening factors that mediate Bevacizumab resistance in PAAD and identified BICC1 as a key mediator for VEGF-independent angiogenesis of PAAD. The gene discussed is BICC1; the disease is pancreatic adenocarcinoma.